Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A nationwide artificial intelligence risk assessment for primary prevention of cardiometabolic diseases

Project description

A smart way to identify high-risk individuals

Undiagnosed disease is an ongoing problem. The sooner the diagnosis, the better the chances of reducing the risk of a person developing devastating complications. As regards diabetes, stroke and coronary artery disease (the leading cause of death in Europe), effective pharmacological and lifestyle interventions are available. This makes it important to identify high-risk individuals at an early stage. But current clinical predictions are usually considered by doctors only when an underlying disease is already suspected. The EU-funded AI-PREVENT project will develop AI approaches to model health trajectories based on nationwide registry data on medications, diagnoses, familial risk and socio-demographic information in order to obtain accurate risk estimates for cardiometabolic disease.

Objective

Diabetes, stroke and coronary artery disease (cardiometabolic diseases) are the leading cause of death in Europe. Given that effective pharmacological and lifestyle interventions are available, it is important to identify high risk individuals at an early stage. Traditionally, this is done using clinical prediction models. However, the established models have substantial limitations: they are often used by doctors only when an underlying disease is already suspected, they are not developed on updated nationally-representative data and they require time-consuming clinical measurements. Thus, a substantial part of the population is not provided with risk assessment. I propose to revolutionize the existing approaches to primary prevention by providing risk assessment of cardiometabolic diseases before an individual even steps into the doctor’s office for a visit. To this end my project has three main objectives:

1) Development of artificial intelligence (AI) approaches to model health trajectories based on nationwide registry data on medications, diagnoses, familial risk and socio-demographic information to obtain accurate risk estimates for cardiometabolic disease. I will integrate high quality data from selected countries that have long traditions of registry data (Finland and Sweden, over 7.5 million individuals).

2) To identify health trajectories that maximize the clinical utility of genetic scores by integrating genetic and registry-based data on > 1 million people to identify subgroups of individuals for whom genetic information might improve risk prediction.

3) Validation of AI and genetic-based risk assessment as first-stage screening via a clinical study in 2800 individuals.

My project leverages the latest developments in AI and high-quality data of unprecedented scale to deliver a paradigm shift with important public health consequences by potentially changing the way cardiometabolic disease risk is assessed.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

ERC-STG - Starting Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2020-STG

See all projects funded under this call

Host institution

HELSINGIN YLIOPISTO
Net EU contribution
€ 1 550 057,00
Address
FABIANINKATU 33
00014 Helsinki
Finland
Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 550 057,00

Beneficiaries (1)